Depatuxizumab mafodotin, also known as ABT-414, is an antibody-drug conjugate (ADC) for cancer treatment. It targets EGFR using a monoclonal antibody and delivers MMAF, a potent cytotoxic agent. This method directly attacks EGFR-overexpressing cancer cells, improving effectiveness and limiting side effects.
Key Features
- Targeted Therapy: Focuses on EGFR, often found in cancers like glioblastoma and lung cancer.
- Mechanism of Action: Binds to EGFR, enters the cancer cell, and releases MMAF. This disrupts microtubules, stopping cell division and causing cell death.
- Precision Medicine: Sends the cytotoxic agent directly to tumors, sparing healthy tissues.
Applications
- Glioblastoma Treatment: Studied for EGFR-positive glioblastoma.
- Lung Cancer Research: Explored for EGFR-expressing lung cancers.
- Targeted Drug Development: Offers insights to improve ADC technology.
- Preclinical Studies: Helps study EGFR-targeting mechanisms.
- Precision Oncology: Aids in developing personalized cancer therapies.
Depatuxizumab mafodotin is a major advancement in cancer therapy, highlighting the potential of antibody-drug conjugates while addressing their challenges.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.